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Background/aim: The aim of this study is to assess the Xpert MTB/RIF assay for diagnosis of the Mycobacterium tuberculosis complex
in clinical samples and to compare the results by reference to the diagnostic method, Bactec MGIT 960.
Materials and methods: A total of 7407 samples were included from patients not primarily suggesting pulmonary or extrapulmonary
tuberculosis (TB), collected from patients required to be screened for TB and excluding TB diagnoses since it was a differential diagnosis.
Also included were a total of 411 samples from patients primarily suggesting pulmonary or extrapulmonary TB.
Results: In the first group, 152 of 7407 samples yielded positive results with the Bactec MGIT 960, 131 (1.77%) were found positive
with Löwenstein–Jensen medium, and 295 (3.99%) were found positive with Ziehl–Neelsen staining. In the second group, 24 (5.8%), 17
(4.1%), and 28 (6.8%) of 411 samples were found positive. Xpert MTB/RIF [27 (6.6%) of 411 samples] detected 3 additional samples as
positive, and these 3 cases were clinically compatible with TB.
Conclusion: The Xpert MTB/RIF assay shows superior performance for the diagnosis of TB. Its usefulness in culture-negative patients
and the best method for integrating this diagnostic method into current tuberculosis diagnostic algorithms both need further study.
Key words: Tuberculosis diagnosis, Mycobacterium tuberculosis complex, Xpert MTB/RIF assay, Bactec MGIT 960

1. Introduction
Tuberculosis (TB) is one of the major global public health
problems despite available potent antituberculosis drugs,
causing nearly 9 million new cases and 2 million deaths per
year (1,2). The emergence of multidrug-resistant tuberculosis
cases, particularly in the 1990s, has become an important
health problem, threatening the control of tuberculosis (3).
The conventional TB diagnosis methods, including direct
microscopic examination by Ehrlich–Ziehl–Neelsen staining,
culture, chest radiography, and tuberculin skin testing, have
limitations and are not always helpful in diagnosing TB (4).
Used as a stand-alone method in some countries, smear
microscopy remains the most universal diagnostic method.
However, smear microscopy identifies only 45% of TB cases
and does not detect drug resistance (2). Although the culture
method is more sensitive, it has significant shortcomings,
including a time period of 2–8 weeks required for a diagnosis
and the need for biosafety precautions and experienced
personnel. It has been considered that each TB patient can
* Correspondence: cemcelik58@gmail.com

infect up to 10–15 persons every year (3). Therefore, delayed
diagnosis prevents disease control, and each patient with
a delayed diagnosis becomes a source of new cases, which
further increases health costs (4).
There has been significant progress in the last decade
in TB diagnostic methods. Molecular methods have
been developed that can identify the Mycobacterium
tuberculosis complex in clinical samples in as short as 2 h
and can also detect drug resistance simultaneously (5,6).
The Xpert MTB/RIF (Cepheid, USA) system is a molecular
diagnostic method based on a real-time polymerase chain
reaction (PCR) mechanism. It has been shown to have a
high sensitivity and specificity for other specimens as well
as for respiratory tract specimens (7–9). Starting from
December 2010, the World Health Organization (WHO)
has recommended the use of the Xpert MTB/RIF system as
one of the onset TB diagnostic tests to diagnose suspected
multidrug-resistant TB or TB infections associated with
human immunodeficiency virus (HIV) (10).
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Molecular diagnostic methods are more expensive
compared to other conventional methods, and this creates
a challenge, particularly in low- and middle-income TBendemic countries. Moreover, how these tests will be
included into the tuberculosis diagnosis algorithm and
at what level they should be performed in healthcare
centers are major questions (6). This study aims primarily
to compare Xpert MTB/RIF system results with BACTEC
MGIT 960, Löwenstein–Jensen (LJ) medium, and direct
microscopic examination methods in detecting the
presence of the M. tuberculosis complex in specimens
collected from suspected tuberculosis patients. The study
also aims to seek answers to the question: should the
Xpert MTB/RIF system be considered in the diagnostic
algorithm of TB, which is included in the differential
diagnosis of many infectious and noninfectious diseases?
2. Materials and methods
This study includes clinical specimens (sputum,
bronchoalveolar lavage, gastric lavage aspirate, urine,
cerebrospinal fluid, and others) tested for the M. tuberculosis
complex at the clinical microbiology laboratories of the
Training and Research Hospital of Cumhuriyet University
between January 2009 and December 2012. Submitted
specimens were classified into two groups. The first group
included 7407 specimens that did not primarily suggest
pulmonary or extrapulmonary TB. The specimens were
collected from patients required to be screened for TB,
excluding TB diagnosis, since it was a differential diagnosis.
The second group included 411 specimens collected from
patients with pulmonary or extrapulmonary TB due to the
presence of at least one of the following (together with the
clinical findings of the patients): findings of chest X-ray,
history of previous TB, family history of TB, or history
of contact with a confirmed TB patient. Tests in the first
group were performed with conventional methods (smear
microscopy, culture by LJ medium, and Bactec MGIT 960)
commonly used to diagnose tuberculosis in the specimens.
In the second group, tuberculosis DNA was studied using
the Xpert MTB/RIF (Cepheid GeneXpert System, USA)

system in specimens, in addition to the above methods.
The Xpert MTB/RIF system was not used for specimens in
the first group due to its high cost. Repeat specimens from
the same patient were excluded from the study.
No homogenization or decontamination procedures
were performed on the specimens for molecular studies.
The specimens and transfer solution (Pour Sample
Reagent) were transferred to 1.5-mL sterile centrifuge
tubes at a ratio of 1/1 and were then incubated at room
temperature for 15 min. A sufficient amount of the mixture
was collected using a sterile Pasteur pipette included in the
kit; this was slowly transferred into the testing cartridge
and the lid was closed. The cartridge was then placed into
the Xpert MTB/RIF device and the system was switched
on. The results were available after 2 h.
The specimens were first homogenized and
decontaminated before being taken into the MGIT 960
system (Becton Dickinson, USA) and the LJ medium.
N-acetyl- L-cysteine and sodium hydroxide (NALC
and NaOH) were used in the homogenization and
decontamination procedures. The specimens were placed
on slides, dry-fixed, stained according to the Ehrlich–
Ziehl–Neelsen (EZN) method, and examined under a
microscope (10 × 100). Tuberculosis–Mycobacterium
tuberculosis complex identification and antimicrobial
sensitivity tests were performed using the BACTEC MGIT
960 system according to the manufacturer’s operational
guidelines. Growth control was done by visual inspection
and by Ziehl–Neelsen staining over the agar surface for LJ
medium isolates.
This study was approved by the Medical Ethics
Committee of Cumhuriyet University. The Youden index
was used for the comparison of the performance of the
diagnostic tests.
3. Results
The distributions of 7407 specimens from group 1 and
411 specimens from group 2, which had been sent to our
laboratory for M. tuberculosis complex tests, are presented
in Table 1.

Table 1. The distribution of clinical specimens in group 1 (n = 7407) and group 2 (n = 411).

1330

Sample

Group 1, n (%)

Group 2, n (%)

Sputum

1521 (20.5)

76 (18.5)

Bronchial lavage

582 (7.9)

23 (5.6)

Urine

1404(18.9)

72 (17.5)

Cerebrospinal fluid

427 (5.8)

38 (9.2)

Gastric lavage

1754 (23.7)

145 (35.3)

Other

1719 (23.2)

57 (13.9)

Total

7407 (100)

411 (100)
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predictive values of the Xpert MTB/RIF system were found
to be 0.88 and 1.00, respectively.

Currently, the gold standard method recognized
in the diagnosis of tuberculosis is the culture method.
Automated culture systems, which are more sensitive and
give quicker results compared to classical culture methods,
are preferred (11–13). The BACTEC MGIT 960 system was
used as the reference method in this study. Although 152
(2.05%) specimens were found to be positive in the first
group, growth was found in 24 (6.5%) clinical specimens
in the second group. Comparisons of clinical specimens in
both groups for methods used and positivity rates are given
in Table 2. Nine of the 24 specimens in group 2 cultured
using BACTEC MGIT 960 that yielded growth were
sputum, 5 were gastric lavage, 4 were bronchial lavage, 3
were pleural fluid, 2 were urine, and one was an abscess
specimen. The Xpert MTB/RIF system also found positive
results in all 24 specimens, which consisted of different
clinical specimens. Furthermore, whereas the BACTEC
MGIT 960 culture system, LJ medium, and EZN methods
found negative results in 3 specimens consisting of one
sputum, one abscess, and one urine specimen, the results
were positive with the Xpert MTB/RIF molecular system.
Cases from which these 3 specimens were collected were
also found to be clinically consistent with tuberculosis.
Antituberculosis treatment was started in these 3 patients
according to positive test results with the Xpert MTB/
RIF molecular system, and the patients were reported as
proven tuberculosis-infected because their symptoms
improved after tuberculosis treatment.
As a result of statistical analyses performed in the
second group by evaluating the test results of the clinical
specimens, the BACTEC MGIT 960 system was used as
the reference method, which showed that the sensitivity
and specificity of the Xpert MTB/RIF system was very
high (Youden index: 0.99). The specificity of the Xpert
MTB/RIF test was found at 0.99 (95% [CL], 0.98–1.00;
384 of 387), with a sensitivity of 1.00. Positive and negative

4. Discussion
The M. tuberculosis complex can affect many organs and
systems. It most commonly causes pulmonary tuberculosis,
constituting the main source of infection in the community
until these patients are diagnosed and treated (14). Clinical
presentations of extrapulmonary tuberculosis should be
considered in the differential diagnosis of many infectious
and noninfectious diseases (15). It can cause acute
conditions such as meningitis and endocarditis, which have
high morbidity and mortality rates, as well as infections
with delayed diagnoses such as chronic osteomyelitis
(16–18). In a study conducted in Turkey, tuberculosis was
found to be the most common cause of infectious reasons
for fever of unknown origin (19). Tuberculosis has even
been considered in the differential diagnosis of arthritis
and of malignancies due to M. tuberculosis complex, which
causes granulomatous lesions (15,20–22). In light of these
data, pulmonary tuberculosis patients, who are the main
source of new pulmonary or extrapulmonary tuberculosis
cases, should be diagnosed immediately. Moreover, early
diagnosis is also important in extrapulmonary TB clinical
presentations, which create no risks for the transmission
of the disease but can cause high morbidity and mortality.
Many nucleic acid amplification test methods require
experienced technicians to perform the tests. Moreover,
these methods require a system where many specimens
are analyzed together and a certain number of specimens
is collected (23). However, the Xpert MTB/RIF system
is simple and can be applied by personnel with little
training. Each specimen can be tested as soon as it arrives
to the laboratory, requiring no pool method where the
specimens are collected. This allows for a quick diagnosis
of tuberculosis, an ideal time for respiratory isolation

Table 2. The comparison of the results of Xpert MTB/RIF assay, Löwenstein–Jensen medium, and Ehrlich–Ziehl–Neelsen BACTEC
using MGIT 960.
Number of positive samples (%)

Group 1
BACTEC
MGIT 960
Group 2

Xpert MTB/RIF

LJ

EZN

Positive (n = 152)

-

118 (77.63)

101 (66.44)

Negative (n = 7255)

-

13 (0.18)

194 (2.61)

Total (n = 7407)

-

131 (1.77)

295 (3.99)

Positive (n = 24)

24 (100)

17 (70.8)

15 (62.5)

Negative (n = 387)

3 (0.7)

0 (0)

13 (3.3)

Total (n = 411)

27 (6.6)

17 (4.1)

28 (6.8)

LJ: Löwenstein–Jensen, EZN: Ehrlich–Ziehl–Neelsen.
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decision-making, and immediate treatment without
delay (6,23,24). The Xpert MTB/RIF test, which contains
probes targeting the 81-bp regions on the rpoB gene in M.
tuberculosis, is a molecular system used to simultaneously
identify M. tuberculosis and rifampicin resistance. Using
this system, the M. tuberculosis complex and rifampicin
resistance can be identified with a single test in 2 h
(6). Blakemore et al., in their study of 79 different M.
tuberculosis and 89 different non-M. tuberculosis strains,
reported that the Xpert MTB/RIF system accurately
identified all 79 M. tuberculosis strains (100%). Helb et
al. reported the system sensitivity as 100% for positive
microscopy and culture specimens, and as 84.6% for
negative microscopy and positive culture specimens (23).
High rates of sensitivity and specificity have been reported
for different clinical specimens (25–27). We reidentified all
M. tuberculosis strains (24 strains) that we identified using
our reference method, using the Xpert MTB/RIF system.
We found high sensitivity and specificity rates in this study
where we attempted to find out the performance of the
Xpert MTB/RIF system.
Certain concentrations of bacteria should be found
in specimens in order to be able to detect positive results
using microscopic and culture methods (28). Rachow et
al. reported that all clinical specimens in which growth
was detected using the culture method were also found
positive with the Xpert MTB/RIF system; in addition, they
found positive results with the Xpert MTB/RIF system in
4 culture-negative clinical specimens (29). In our study, 3
specimens found to be negative with the BACTEC MGIT
960 system and 10 specimens that were negative with LJ
medium were found to be positive using the Xpert MTB/
RIF system. We consider that the Xpert MTB/RIF system
detects bacteria with lower concentrations in clinical
specimens, yielding more positive results than other
methods used in our study.
More than 95% of new tuberculosis cases and most
mortalities associated with tuberculosis are seen in
developing countries (2,23). The diagnosis, treatment,
follow-up, and care of many patients in these countries are
carried out in health centers depending on a microscopy
center including staining with the EZN method to detect
acid-resistant bacilli (ARB) (6,23,30). Although direct
microscopy is the most common method worldwide,
only 45% of tuberculosis cases were found positive in
2009 (6,31). In our study, LJ staining was positive in
only 76.7% (135/176) of all culture-positive cases. There
are also bacteria with positive ARB microscopy other
than mycobacteria (Nocardia, etc.) (32,33). In our study,
207 (2.7%) specimens that were found positive with the
staining method were not found positive with any other
methods we used. We attribute this to ARB-positivestained bacteria other than mycobacteria.
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The need for more secure and quicker diagnostic tests
to control tuberculosis globally is of key importance,
especially in countries with highly endemic TB and
high HIV seroprevalence (34). The high cost of the
Xpert MTB/RIF system ultimately leads to its limited
use (23,34). Tuberculosis is a disease more commonly
seen in developing countries. This system should be
applicable in these countries at a special price, which
should be competitive enough to keep pace with classical
culture and conventional methods (23). However, the
classical diagnostic methods used at these centers are not
sufficiently sensitive, and microscopic examination is very
dependent on the performance of the person in question,
and this results in inability to diagnose the case. This is one
of the most important factors contributing to the inability
to control tuberculosis worldwide. It has been argued that
the Xpert MTB/RIF system’s applicability at these centers
within the bounds of possibility could be a very important
opportunity to control the disease (6,23). It has also been
reported that in order to eliminate tuberculosis by the year
2050, its incidence should be reduced by an average of 16%
every year. It has also been argued that a single method
cannot achieve this target, and that new diagnostic
methods, particularly nucleic acid amplification methods,
could contribute greatly to its elimination (6,35). In our
study, we included the Xpert MTB/RIF system into the
onset diagnostic tests only in the presence of findings
and risk factors that would support a TB diagnosis, due
to its high costs. We consider that the patients should be
diagnosed within 2 h, which will ensure the immediate
start of effective treatment for the patients; it will also
ensure that the decision of isolation, which plays a very
important role in controlling tuberculosis, can be taken
during the early period. We also think that TB diagnosis
in culture-negative patients could play an effective role in
reducing morbidity and mortality rates associated with
TB, and in preventing the spread of TB worldwide.
In conclusion, although the Xpert MTB/RIF system
is costly, certain points should be considered in costeffectiveness studies. It will certainly increase the costs
of tuberculosis diagnosis. However, the reduction in
morbidity and mortality with early diagnosis and especially
the reduced spread of tuberculosis should be considered.
Diagnosis algorithms should also be considered in cases
with risk factors such as a history of previous TB, family
history of TB, and history of contact with a confirmed
TB patient, or in suspected cases as a factor of a possible
infection developing in immunosuppressive patients or
that can present with high mortality. We consider that
molecular diagnostic methods can be better appreciated
with long-term cost-effectiveness studies, which consider
potential long-term issues, instead of short-term costeffectiveness studies.
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